Bertrand Dupont - DBV Technologies Insider

DBVT -- USA Stock  

USD 23.88  0.15  0.62%

  Founder
Mr. Bertrand Dupont is Industrial Director of DBV Technologies SA. He is also the cofounder of the Company. Prior to cofounding DBV Technologies, Mr. Dupont qualified as an engineer from the Ecole Nationale Superieure des Arts et Metiers in Paris and went on to pursue a career in teaching and consultancy. From 1996, Mr. Dupont worked in biomedical research and from 2000 was involved in the development of VIASKIN patch technology and application system.
Age: 64  Founder Since 2013      
33 1 55 42 78 78  http://www.dbv-technologies.com

Management Efficiency

The company has return on total asset (ROA) of (38.95) % which means that it has lost $38.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (79.24) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 4.83 M in liabilities with Debt to Equity (D/E) ratio of 3.1 implying the company greatly relies on financing operations through barroing. DBV Technologies S A has Current Ratio of 4.28 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. DBV Technologies operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 244 people.DBV Technologies S A (DBVT) is traded on BATS Exchange in USA. It is located in FRANCE and employs 244 people. DBV Technologies is listed under Pharmaceutical Products category by Fama And French industry classification.

DBV Technologies S Leadership Team

Rafaele Tordjman, Director - Representative of Sofinnova Partners
Bertrand Dupont, Co-Founder and Sr. Executive VP of Technology
Pascale Ehouarn, Industrial Development and Production Director
Claude Thebault, Medical Director
Veronique Foutel, Director of Strategic Marketing
Wence Agbotounou, Chief Clinical Trial Officer
Laurent Martin, Director of Regulatory Affairs
Didier Hoch, Director
Rafale Tordjman, Director - Representative of Sofinnova Partners
George Horner, Director
Hugh Sampson, Chief Scientific Officer
Torbjorn Bjerke, Independent Director
Charles Ruban, Chief Development Officer
Nathalie Donne, Director of Bus. Devel. and Corporate Communication
PierreHenri Benhamou, Chairman of the Board, CEO
Torbjrn Bjerke, Independent Director
Mailys Ferrere, Director
Lucie Mondoulet, Director of Research Department
Chahra Louafi, Director - Representative of CDC Entreprises (Innobio)
Peter Hutt, Independent Director
David Schilansky, COO

Stock Performance Indicators

Did you try this?

Run CEO Directory Now

   

CEO Directory

Screen CEOs from public companies around the world
All  Next Launch CEO Directory

DBV Technologies Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for DBV Technologies and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.
Search macroaxis.com